Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 6/20 | 0.34 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.33 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.33 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14393617 | 0.92 | GRIN2B (0.32) | GRIN2BTPSAB1TPSD1TPSG1F2 | |
| SCHEMBL13625767 | 0.91 | CYP1A2 (0.36) | ADORA3ADORA2A | |
| SCHEMBL13625769 | 0.91 | GRIN2B (0.40) | GRIN2B | |
| SCHEMBL13625768 | 0.84 | ADORA3 (0.32) | ADORA3KMT2A | |
| SCHEMBL13625863 | 0.83 | ADORA3 (0.36) | GRIN2BADORA3ADORA2AKMT2A | |
| SCHEMBL13625892 | 0.82 | GRIN2B (0.40) | GRIN2B | |
| SCHEMBL13626076 | 0.82 | ADORA3 (0.34) | ADORA3ADORA2AADORA2BKMT2A | |
| SCHEMBL13625683 | 0.82 | ADORA3 (0.34) | ADORA3ADORA2AADORA2B | |
| SCHEMBL13819681 | 0.82 | ACACB (0.32) | KMT2A | |
| SCHEMBL13819686 | 0.81 | MEN1 (0.31) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090280059-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | PGXHEALTH, LLC (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280059-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | ADORA2A, ADORA1, ADORA3 | GRIN2B 453/4885TPSAB1 1487/4885TPSD1 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.